Clinics in Dermatology
Volume 24, Issue 5 , Pages 393-413 , September 2006

Sjögren's syndrome in dermatology

  • Robert I. Fox, MD

      Affiliations

    • Rheumatology Clinic Scripps Memorial Hospital and Research Foundation, La Jolla, CA 92037, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Alice Y. Liu, MD

      Affiliations

    • Dermatologist Medical Group of North County, Inc, Scripps Memorial Hospital, La Jolla, CA 92037, USA

References 

  1. Mikulicz JH. Uber eine eigenartige symmetrische Erkrankung der Tranen- und Mundspeicheldrusen. In:  Billroth GT editors. Beitr Chir Fortschr. 1892;p. 610–630[Stuttgart]
  2. Daniels TE, Fox PC. Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am. 1992;18:571–589
  3. Morgan W, Castleman B. A clinicopathologic study of Mikulicz's disease. Am J Pathol. 1953;29:471–503
  4. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren's syndrome: a clinical, pathological and serological study of 62 cases. Medicine (Baltimore). 1956;44:187–231
  5. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol. 2004;33:39–43
  6. Fox RI, Tornwall J, Michelson P. Current issues in the diagnosis and treatment of Sjogren's syndrome. Curr Opin Rheumatol. 1999;11:364–371
  7. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc. 2001;76:593–599
  8. Cimaz R, Casadei A, Rose C, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162:661–665
  9. Fox RI, Robinson C, Curd J, Michelson P, Bone R, Howell FV. First international symposium on Sjögren's syndrome: suggested criteria for classification. Scand J Rheumatol. 1986;562:28–30
  10. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjogren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome. Ann Rheum Dis. 1994;53:637–647
  11. Fox R. Sjogren's syndrome: progress and controversies. Med Clin North Am. 1997;17:434–441
  12. Vitali C. Classification criteria for Sjogren's syndrome. Ann Rheum Dis. 2003;62:94–95[author reply 95]
  13. Chan EKL, Sullivan KF, Fox RI, Tan EM. Sjögren's syndrome nuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes. J Autoimmun. 1989;2:321–327
  14. Ben-Chetrit E, Fox RI, Tan EM. Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum. 1990;33:349–355
  15. Harley JB, Alexander EL, Bias WB, et al. Anti-Ro (SS-A) and Anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum. 1986;29:196–206
  16. Fei HM, Kang H-I, Scharf S, Erlich H, Peebles C, Fox RI. Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody SS-B production. J Clin Lab Anal. 1991;5:382–391
  17. Hamilton RG, Harley JB, Bias WB, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematous. Arthritis Rheum. 1988;31:446–505
  18. Rader MD, O'Brien C, Liu Y, Harley JB, Reichlin M. Heterogeneity of the Ro/SSA antigen. J Clin Invest. 1989;83:1293–1298
  19. Gaither KK, Fox OW, Yamagata H, Mamula MJ, Reichlin M, Harley JB. Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest. 1987;79:841–846
  20. Sestak AL, Harley JB, Yoshida S, Reichlin M. Lupus/Sjögren's autoantibody specificities in sera with paraproteins. J Clin Invest. 1987;80:138–144
  21. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–1611
  22. Lightfoot R. Cost effective use of laboratory tests in rheumatology. Bull Rheum Dis. 1997;46:1–3
  23. Daniels Taf, P.C. . Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am. 1992;18:571–583
  24. Fox RI, Howell FV. Oral problems in patients with Sjögren's syndrome. Scand J Rheumatol. 1986;S61:194–200
  25. Bone RC, Fox RI, Howell FV, Fantozzi R. Sjögren's syndrome: new immunologic assessments for a persistent clinical problem. Laryngoscope. 1985;95:295–299
  26. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Arthritis Rheum. 1984;27:147–156
  27. Daniels TE, Wu AJ. Xerostomia-clinical evaluation and treatment in general practice. J Calif Dent Assoc. 2000;28:933–941
  28. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum. 2002;47:520–524
  29. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol. 2002;29:938–944
  30. Tapinos NI, Polihronis M, Tzioufas AG, Moutsopoulos HM. Sjogren's syndrome. Autoimmune epithelitis. Adv Exp Med Biol. 1999;455:127–134
  31. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol. 1996;79:50–59
  32. Salomonsson S, Larsson P, Tengner P, Mellquist E, Hjelmstrom P, Wahren-Herlenius M. Expression of the B cell–attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol. 2002;55:336–342
  33. Xanthou G, Polihronis M, Tzioufas AG, Paikos S, Sideras P, Moutsopoulos HM. “Lymphoid” chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum. 2001;44:408–418
  34. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199:173–183
  35. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376
  36. Vaughan JH, Nguyen MD, Valbracht JR, Patrick K, Rhodes GH. Epstein-Barr virus–induced autoimmune responses: II. Immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes. Presence in autoimmune disease. J Clin Invest. 1995;95:1316–1327
  37. Li JM, Horsfall AC, Maini RN. Anti-La (SS-B) but not anti-Ro52 (SS-A) antibodies cross-react with laminin—a role in the pathogenesis of congenital heart block?. Clin Exp Immunol. 1995;99:316–324
  38. Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol. 2005;141:148–154
  39. Nakamura H, Kawakami A, Yamasaki S, et al. Expression and function of X chromosome–linked inhibitor of apoptosis protein in Sjogren's syndrome. Lab Invest. 2000;80:1421–1427
  40. Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep. 2003;5:311–316
  41. Sawalha AH, Potts R, Schmid WR, Scofield RH, Harley JB. The genetics of primary Sjogren's syndrome. Curr Rheumatol Rep. 2003;5:324–332
  42. Scofield RH, Kurien BT, Zhang F, et al. Protein-protein interaction of the Ro-ribonucleoprotein particle using multiple antigenic peptides. [In Process Citation] Mol Immunol. 1999;36:1093–1106
  43. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11:85–89
  44. Heinlen LD, McClain MT, Kim X, et al. Anti-Ro and anti-nRNP response in unaffected family members of SLE patients. Lupus. 2003;12:335–337
  45. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533
  46. Kaufman KM, Kirby MY, McClain MT, Harley JB, James JA. Lupus autoantibodies recognize the product of an alternative open reading frame of SmB/B′. Biochem Biophys Res Commun. 2001;285:1206–1212
  47. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62:168–171
  48. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol. 2004;202:496–502
  49. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003;197:777–788
  50. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma–induced T cell–attracting chemokines, interferon-gamma–inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum. 2002;46:2730–2741
  51. Bolstad AI, Jonsson R. Gene therapeutics in Sjogren's syndrome. Expert Opin Biol Ther. 2005;5:763–772
  52. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534–1544
  53. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte–associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum. 2003;48:174–185
  54. Konttinen YT, Hukkanen M, Kemppinen P, et al. Peptide-containing nerves in labial salivary glands in Sjögren's syndrome. Arthritis Rheum. 1992;35:815–820
  55. Konttinen YT, Kasna-Ronkainen L. Sjogren's syndrome: viewpoint on pathogenesis. One of the reasons I was never asked to write a textbook chapter on it. Scand J Rheumatol Suppl. 2002;15–22
  56. Tsubota K, Hirai S, King LS, Agre P, Ishida N. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjogren's syndrome. Lancet. 2001;357:688–689
  57. Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab Invest. 2001;81:143–148
  58. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–651
  59. Fox RI, Stern M. Sjogren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl. 2002;116:3–13
  60. Pflugfelder SC. Differential diagnosis of dry eye conditions. Adv Dent Res. 1996;10:9–12
  61. Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol Suppl. 2000;61:6–10
  62. Allison PJ, Locker D, Feine JS. The relationship between dental status and health-related quality of life in upper aerodigestive tract cancer patients. Oral Oncol. 1999;35:138–143
  63. Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33:95–106
  64. Beroukas D, Goodfellow R, Hiscock J, Jonsson R, Gordon TP, Waterman SA. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome. Lab Invest. 2002;82:203–210
  65. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol. 2001;101:249–263
  66. Fisher A, Heldman E, Gurwitz D, et al. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann N Y Acad Sci. 1996;777:189–196
  67. Bergdahl J, Bergdahl M. Environmental illness: evaluation of salivary flow, symptoms, diseases, medications, and psychological factors. Acta Odontol Scand. 2001;59:104–110
  68. Yousem DM, Kraut MA, Chalian AA. Major salivary gland imaging. Radiology. 2000;216:19–29
  69. Tonami H, Higashi K, Matoba M, Yokota H, Yamamoto I, Sugai S. A comparative study between MR sialography and salivary gland scintigraphy in the diagnosis of Sjogren syndrome. J Comput Assist Tomogr. 2001;25:262–268
  70. Salaffi F, Argalia G, Carotti M, Giannini FB, Palombi C. Salivary gland ultrasonography in the evaluation of primary Sjogren's syndrome. Comparison with minor salivary gland biopsy. J Rheumatol. 2000;27:1229–1236
  71. Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjogren's syndrome. Curr Rheumatol Rep. 2003;5:297–303
  72. Alexander EL, Provost TT. Cutaneous manifestations of primary Sjögren's syndrome: a reflection of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol. 1983;80:386–391
  73. Ito Y, Kanda N, Mitsui H, et al. Cutaneous manifestations of Sjogren's syndrome associated with myasthenia gravis. [letter] Br J Dermatol. 1999;141:362–363
  74. Sais G, Admella C, Fantova MJ, Montero JC. Lymphocytic autoimmune hidradenitis, cutaneous leucocytoclastic vasculitis and primary Sjogren's syndrome. Br J Dermatol. 1998;139:1073–1076
  75. Gemignani F, Marbini A, Pavesi G, et al. Peripheral neuropathy associated with primary Sjogren's syndrome. J Neurol Neurosurg Psychiatry. 1994;57:983–986
  76. Hebbar M, Lassalle P, Janin A, et al. E-Selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Role of resident mast cell–derived tumor necrosis factor alpha. Arthritis Rheum. 1995;38:406–412
  77. Cho CS, Park SH, Min JK, Lee SH, Kim HY. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjogren's syndrome. Korean J Intern Med. 1997;12:176–181
  78. Kyle R, Gleich G, Bayrid E, Vaughn JH. Benign hyperglobulinemic purpura of Waldenstrom. Medicine (Baltimore). 1971;50:113–123
  79. Fox RI, Carson DA, Chen P, Fong S. Characterization of a cross reactive idiotype in Sjögren's syndrome. Scand J Rheumatol. 1986;561:83–88
  80. Fox RI, Chen PP, Carson DA, Fong S. Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjögren's syndrome. J Immunol. 1986;136:477–483
  81. Fox RI, Fong S, Chen PP, Kipps TJ. Autoantibody production in Sjögren's syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. In Vivo. 1988;2:47–56
  82. Fong S, Chen PP, Fox RI, et al. The diversity and idiotypic pattern of human rheumatoid factors in disease. Concepts Immunopathol. 1988;5:168–191
  83. Ramos-Casals M, Cervera R, Yague J, et al. Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum. 1998;28:200–205
  84. Bernacchi E, Amato L, Parodi A, et al. Sjogren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol. 2004;22:55–62
  85. Alexander E, Provost TT. Sjögren's syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol. 1987;123:801–810
  86. Provost TT, Watson R, Simmons OBE. Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome. Lupus. 1997;6:105–111
  87. Konishi M, Ohosone Y, Matsumura M, et al. Mixed-cryoglobulinemia associated with cutaneous vasculitis and pulmonary symptoms. Intern Med. 1997;36:62–67
  88. Ferri C, La Civita L, Longombardo G, Zignego AL, Pasero G. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus. 1998;7:275–279
  89. Ferri C, Bernini L, Cecchetti R, et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol. 1991;18:1826–1832
  90. O'Donnell B, Black AK. Urticarial vasculitis. Int Angiol. 1995;14:166–174
  91. Provost TT, Watson R, Simmons-O'Brien E. Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome. Lupus. 1997;6:105–111
  92. Provost TT, Watson R. Cutaneous manifestations of Sjogren's syndrome. Rheum Dis Clin North Am. 1992;18:609–616
  93. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med. 1997;126:866–873
  94. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med. 1996;101:576–583
  95. Navarro M, Cervera R, Font J, et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus. 1997;6:521–526
  96. Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GRV, Fox RI. Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. Ann Rheum Dis. 1992;51:495–498
  97. Roguedas AM, Misery L, Sassolas B, Le Masson G, Pennec YL, Youinou P. Cutaneous manifestations of primary Sjogren's syndrome are underestimated. Clin Exp Rheumatol. 2004;22:632–636
  98. Jubert C, Cosnes A, Clerici T, et al. Sjogren's syndrome and cutaneous B cell lymphoma revealed by anetoderma. Arthritis Rheum. 1993;36:133–134
  99. Pablos JL, Cogolludo V, Pinedo F, Carreira PE. Subcutaneous nodular amyloidosis in Sjögren's syndrome. Scand J Rheumatol. 1993;22:250–251
  100. Yoneyama K, Tochigi N, Oikawa A, Shinkai H, Utani A. Primary localized cutaneous nodular amyloidosis in a patient with Sjogren's syndrome: a review of the literature. J Dermatol. 2005;32:120–123
  101. Yamamoto T, Katayama I, Nishioka K. Analysis of T cell receptor Vbeta repertoires of annular erythema associated with Sjogren's syndrome. Eur J Dermatol. 1998;8:248–251
  102. Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83:96–106
  103. Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol. 2005;12:145–149
  104. Pirildar T, Tikiz C, Ozkaya S, et al. Endothelial dysfunction in patients with primary Sjogren's syndrome. Rheumatol Int. 2005;25:536–539
  105. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 2004;50:882–891
  106. Tektonidou M, Kaskani E, Skopouli FN, Moutsopoulos HM. Microvascular abnormalities in Sjogren's syndrome: nailfold capillaroscopy. Rheumatology (Oxford). 1999;38:826–830
  107. Gyulai R, Kiss M, Mehravaran M, et al. Atypical autoimmune blistering dermatosis associated with Sjogren's syndrome. Acta Derm Venereol. 2002;82:462–464
  108. Ruzicka T, Faes J, Bergner T, Peter RU, Braun-Falco O. Annular erythema associated with Sjogren's syndrome: a variant of systemic lupus erythematosus. J Am Acad Dermatol. 1991;25:557–560
  109. Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome–associated neuropathy. Brain. 2005;128:2518–2534
  110. Watanabe T, Tsuchida T, Furue M, Yoshinoya S. Annular erythema, dermatomyositis, and Sjogren's syndrome. Int J Dermatol. 1996;35:285–287
  111. Watanabe T, Tsuchida T, Ito Y, Kanda N, Ueda Y, Tamaki K. Annular erythema associated with lupus erythematosus/Sjogren's syndrome. J Am Acad Dermatol. 1997;36(2 Pt 1):214–218
  112. Katayama Y, Kohriyama K. Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases. J Rheumatol. 2001;28:288–291
  113. Katayama I, Yamamoto T, Otoyama K, Matsunaga T, Nishioka K. Clinical and immunological analysis of annular erythema associated with Sjogren syndrome. Dermatology. 1994;189(Suppl 1):14–17
  114. Miyagawa S, Iida T, Fukumoto T, Matsunaga T, Yoshioka A, Shirai T. Anti-Ro/SSA-associated annular erythema in childhood. Br J Dermatol. 1995;133:779–782
  115. Haimowitz JE, McCauliffe DP, Seykora J, Werth VP. Annular erythema of Sjogren's syndrome in a white woman. J Am Acad Dermatol. 2000;42:1069–1072
  116. Pease CT, Shattles W, Barrett NK, Maini RN. The arthropathy of Sjogren's syndrome. Br J Rheumatol. 1993;32:609–613
  117. Fox RI. Sjogren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs. 2000;9:2007–2016
  118. Lindvall B, Bengtsson A, Ernerudh J, Eriksson P. Subclinical myositis is common in primary Sjogren's syndrome and is not related to muscle pain. J Rheumatol. 2002;29:717–725
  119. Bonafede RP, Downey DC, Bennett RM. An association of fibromyalgia with primary Sjogren's syndrome: a prospective study of 72 patients. J Rheumatol. 1995;22:133–136
  120. Quismorio FP. Pulmonary involvement in primary Sjogren's syndrome. Curr Opin Pulm Med. 1996;2:424–428
  121. Battista G, Zompatori M, Poletti V, Canini R. Thoracic manifestations of the less common collagen diseases. A pictorial essay. Radiol Med (Torino). 2003;106:445–451[quiz 452-3]
  122. Constantopoulos SH, Tsianos EV, Moutsopoulos HM. Pulmonary and gastrointestinal manifestations of Sjogren's syndrome. Rheum Dis Clin North Am. 1992;18:617–635
  123. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22(Spec No):S151–S165
  124. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33:276–277
  125. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol. 2004;77:103–104
  126. Gyongyosi M, Pokorny G, Jambrik Z, et al. Cardiac manifestations in primary Sjogren's syndrome. Ann Rheum Dis. 1996;55:450–454
  127. Andonopoulos AP, Christodoulou J, Ballas C, Bounas A, Alexopoulos D. Autonomic cardiovascular neuropathy in Sjogren's syndrome. A controlled study. J Rheumatol. 1998;25:2385–2388
  128. Press J, Uziel Y, Laxer RM, Luy L, Hamilton RM, Silverman ED. Long-term outcome of mothers of children with complete congenital heart block. Am J Med. 1996;100:328–332
  129. Borda E, Leiros CP, Bacman S, Berra A, Sterin-Borda L. Sjogren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Int J Cardiol. 1999;70:23–32
  130. Gamron S, Barberis G, Onetti CM, et al. Mesangial nephropathy in Sjogren's syndrome. Scand J Rheumatol. 2000;29:65–67
  131. Siamopoulos KC, Elisaf M, Moutsopoulos HM. Hypokalaemic paralysis as the presenting manifestation of primary Sjogren's syndrome. Nephrol Dial Transplant. 1994;9:1176–1178
  132. Fulop M, Mackay M. Renal tubular acidosis, Sjogren syndrome, and bone disease. Arch Intern Med. 2004;164:905–909
  133. Nishimagi E, Kawaguchi Y, Terai C, Kajiyama H, Hara M, Kamatani N. Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome. Intern Med. 2001;40:1059–1063
  134. Dabadghao S, Aggarwal A, Arora P, Pandey R, Misra R. Glomerulonephritis leading to end stage renal disease in a patient with primary Sjogren syndrome. Clin Exp Rheumatol. 1995;13:509–511
  135. Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis–like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. Am J Med. 2003;115:62–65
  136. Shibata S, Ubara Y, Sawa N, et al. Severe interstitial cystitis associated with Sjogren's syndrome. Intern Med. 2004;43:248–252
  137. Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet. 2001;358:1875–1876
  138. Feist E, Kuckelkorn U, Dorner T, et al. Autoantibodies in primary Sjogren's syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum. 1999;42:697–702
  139. Collin P, Karvonen AL, Korpela M, Laippala P, Helin H. Gastritis classified in accordance with the Sydney system in patients with primary Sjogren's syndrome. Scand J Gastroenterol. 1997;32:108–111
  140. Raderer M, Osterreicher C, Machold K, et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol. 2001;12:937–939
  141. Invernizzi P, Battezzati PM, Crosignani A, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol. 1998;114:448–454
  142. Tishler M, Alosachie I, Barka N, et al. Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol. 1995;13:497–500
  143. Zukowski TH, Jorgensen RA, Dickson ER, Lindor KD. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. Am J Gastroenterol. 1998;93:958–961
  144. Sheikh SH, Shaw-Stiffel TA. The gastrointestinal manifestations of Sjogren's syndrome. Am J Gastroenterol. 1995;90:9–14
  145. Collin P, Reunala T, Rasmussen M, et al. High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J Gastroenterol. 1997;32:1129–1133
  146. D'Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL. Thyroid dysfunction in primary Sjogren's syndrome: a long-term follow-up study. Arthritis Rheum. 2003;49:804–809
  147. Perez B, Kraus A, Lopez G, Cifuentes M, Alarcon-Segovia D. Autoimmune thyroid disease in primary Sjogren's syndrome. Am J Med. 1995;99:480–484
  148. Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis. 2004;63:1159–1161
  149. Nishimori I, Okazaki K, Yamamoto Y, Morita M, Tamura S, Yamamoto Y. Specific cellular immune responses to pancreatic antigen in chronic pancreatitis and Sjögren's syndrome. J Clin Immunol. 1993;13:265–271
  150. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, Tzioufas AG, Moutsopoulos HM. Hypofunction of the stress axis in Sjogren's syndrome. J Rheumatol. 1998;25:1508–1514
  151. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888–892
  152. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum. 1999;42:1765–1772
  153. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766–775
  154. Nishimura M, Miyajima S, Okada N. Salivary gland MALT lymphoma associated with Helicobacter pylori infection in a patient with Sjogren's syndrome. [In Process Citation] J Dermatol. 2000;27:450–452
  155. Josephs SF, Buchbinder A, Streicher HZ, et al. Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B-cell lymphoma tissues of three patients. Leukemia. 1988;2:132–135
  156. Nakamura H, Kawakami A, Tominaga M, et al. Relationship between Sjogren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients [In Process Citation]. J Lab Clin Med. 2000;135:139–144
  157. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317–1321
  158. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280–291
  159. Urban PP, Keilmann A, Teichmann EM, Hopf HC. Sensory neuropathy of the trigeminal, glossopharyngeal, and vagal nerves in Sjogren's syndrome. J Neurol Sci. 2001;186:59–63
  160. Barendregt PJ, van Den Bent MJ, van Raaij-Van Den Aarssen VJ, et al. Involvement of the peripheral nervous system in primary Sjogren's syndrome. Ann Rheum Dis. 2001;60:876–881
  161. Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology. 1997;48:855–862
  162. Rosler DH, Conway MD, Anaya JM, et al. Ischemic optic neuropathy and high-level anticardiolipin antibodies in primary Sjogren's syndrome. Lupus. 1995;4:155–157
  163. Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE. Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med. 1986;104:323–330
  164. Simmons-O'Brien E, Chen S, Watson R, et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine (Baltimore). 1995;74:109–130
  165. Pender MP. Recent progress in the diagnosis and treatment of multiple sclerosis. J Clin Neurosci. 1999;6:367–372
  166. de Seze J, Devos D, Castelnovo G, et al. The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis. Neurology. 2001;57:1359–1363
  167. Fisher A. Muscarinic receptor agonists in Alzheimer's disease. CNS Drugs. 1999;12:197–214
  168. Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J Rheumatol. 1994;21:2039–2045
  169. van Dam AP, Wekking EM, Callewaert JA, et al. Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol Int. 1994;14:57–62
  170. Lass P, Krajka-Lauer J, Homziuk M, et al. Cerebral blood flow in Sjogren's syndrome using 99Tcm-HMPAO brain SPET. Nucl Med Commun. 2000;21:31–35
  171. Belin C, Moroni C, Caillat-Vigneron N, et al. Central nervous system involvement in Sjogren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT [In Process Citation]. Ann Med Interne (Paris). 1999;150:598–604
  172. Spezialetti R, Bluestein HG, Peter JB, Alexander EL. Neuropsychiatric disease in Sjogren's syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med. 1993;95:153–160
  173. Tensing EK, Solovieva SA, Tervahartiala T, et al. Fatigue and health profile in sicca syndrome of Sjogren's and non–Sjogren's syndrome origin. Clin Exp Rheumatol. 2001;19:313–316
  174. Lwin CT, Bishay M, Platts RG, Booth DA, Bowman SJ. The assessment of fatigue in primary Sjogren's syndrome. Scand J Rheumatol. 2003;32:33–37
  175. Tishler M, Barak Y, Paran D, Yaron M. Sleep disturbances, fibromyalgia and primary Sjogren's syndrome. Clin Exp Rheumatol. 1997;15:71–74
  176. Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol. 2005;20:71–74
  177. Musadiq M, Mukherji S, Sandramouli S. Pyogenic granuloma following silicone punctal plugs: report of two cases. Orbit. 2005;24:149–151
  178. Kim BM, Osmanovic SS, Edward DP. Pyogenic granulomas after silicone punctal plugs: a clinical and histopathologic study. Am J Ophthalmol. 2005;139:678–684
  179. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005;89:1363–1367
  180. Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol. 2005;8:225–232
  181. Aragona P, Stilo A, Ferreri F, Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients. Eye. 2005;19:535–539
  182. Papas AS, Joshi A, MacDonald SL, Maravelis-Splagounias L, Pretara-Spanedda P, Curro FA. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993;59: 171-4, 177-9.
  183. Papas AS, Joshi A, Belanger AJ, Kent RL, Palmer CA, DePaola PF. Dietary models for root caries. Am J Clin Nutr. 1995;61:417S–422S
  184. Papas AS, Joshi A, Palmer CA, Giunta JL, Dwyer JT. Relationship of diet to root caries. Am J Clin Nutr. 1995;61:423S–429S
  185. Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjogren syndrome. Pharmacology. 2005;74:100–105
  186. Christensen LB, Petersen PE, Thorn JJ, Schiodt M. Dental caries and dental health behavior of patients with primary Sjogren syndrome. Acta Odontol Scand. 2001;59:116–120
  187. Schiodt M, Christensen LB, Petersen PE, Thorn JJ. Periodontal disease in primary Sjogren's syndrome. Oral Dis. 2001;7:106–108
  188. Isidor F, Brondum K, Hansen HJ, Jensen J, Sindet-Pedersen S. Outcome of treatment with implant-retained dental prostheses in patients with Sjogren syndrome. Int J Oral Maxillofac Implants. 1999;14:736–743
  189. Robinson C, Yamciuka S, Alford C, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of NOD mouse model for Sjogren's syndrome. Proc Natl Acad Sci U S A. 1997;94:5767–5771
  190. Yamamoto H, Ishibashi K, Nakagawa Y, et al. Detection of alterations in the levels of neuropeptides and salivary gland responses in the non-obese diabetic mouse model for autoimmune sialoadenitis. Scand J Immunol. 1997;45:55–61
  191. Wu AJ, Fox PC. Sjogren's syndrome. Semin Dermatol. 1994;13:138–143
  192. Wu AJ. The oral component of Sjogren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep. 2003;5:304–310
  193. Hay KD, Morton RP. The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia. N Z Dent J. 2003;99:46–48
  194. Hay KD, Thomson WM. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:271–275
  195. Pers JO, d'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome?. Arthritis Rheum. 2005;52:2411–2414
  196. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34–39
  197. Castillo JL, Milgrom P. Fluoride release from varnishes in two in vitro protocols. J Am Dent Assoc. 2004;135:1696–1699
  198. Castillo JL, Milgrom P, Kharasch E, Izutsu K, Fey M. Evaluation of fluoride release from commercially available fluoride varnishes. J Am Dent Assoc. 2001;132:1389–1392[quiz 1459-1460]
  199. Banting DW, Papas A, Clark DC, Proskin HM, Schultz M, Perry R. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology. 2000;17:67–76
  200. Papas AS, Fernandez MM, Castano RA, Gallagher SC, Trivedi M, Shrotriya RC. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogren's syndrome. Adv Exp Med Biol. 1998;438:973–978
  201. Katelaris CH. Pilocarpine for dry mouth and dry eye in Sjogren's syndrome. Curr Allergy Asthma Rep. 2005;5:321
  202. Wall GC, Magarity ML, Jundt JW. Pharmacotherapy of xerostomia in primary Sjogren's syndrome. Pharmacotherapy. 2002;22:621–629
  203. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748–754
  204. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988;85:62–67
  205. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5(Suppl 1):S31–S36
  206. Wallace D. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994;20:243–263
  207. Kruize A, Hene R, Kallenberg C, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–364
  208. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23:292–296
  209. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment [see comments]. Am J Respir Crit Care Med. 1996;154(3 Pt 1):794–799
  210. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996;14:555–558
  211. Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol. 1998;25:896–899
  212. Wallace DJ. Management of lupus erythematosus: recent insights. Curr Opin Rheumatol. 2002;14:212–219
  213. Dalavanga YA, Detrick B, Hooks JJ, Drosos AA, Moutsopoulos HM. Effect of cyclosporin A (CyA) on the immunopathological lesion of the minor salivary glands from patients with Sjögren's syndrome. Ann Rheum Dis. 1990;46:89–92
  214. Gross WL. New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol. 1999;11:41–46
  215. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–2375
  216. Marriette X. Lack of benefit of infliximab in Sjogren's syndrome. Arthritis Rhem. 2003;[abstract S19]
  217. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol. 2004;31:96–101
  218. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–2245
  219. Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des. 2003;9:279–288
  220. Bowman SJ. Collaborative research into outcome measures in Sjogren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl. 2002;23–27
  221. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004;50:2048–2065
  222. Buyon JP. Neonatal lupus. Curr Opin Rheumatol. 1996;8:485–490
  223. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164:1275–1284

☆ Sjögren's syndrome in Clinics in Dermatology issue entitled “Rheumatology and Dermatology Interface” (edited by Jane M Grant-Kels, MD [grant@nso1.uchc.edu], Marti J Rothe, MD [rothe@nso1.uchc.edu], and Philip Mease, MD [pmease@nwlink.com]).

PII: S0738-081X(06)00097-6

doi: 10.1016/j.clindermatol.2006.07.005

Clinics in Dermatology
Volume 24, Issue 5 , Pages 393-413 , September 2006

Article Tools

* Image Usage & Resolution